-
Ligand Announces Positive Preclinical Data
Monday, December 12, 2011 - 5:30pm | 89Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from preclinical studies on its granulocyte colony stimulating factor receptor program were featured in a poster presentation today at the 53rd Annual Meeting of the American Society of Hematology in San Diego. Ligand has...
-
Investor Ideas' Biotech/ Pharma Stocks To Watch: Friday's Gainers
Monday, December 12, 2011 - 12:46pm | 522Point Roberts, WA - December 12, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Friday, December 09, 2011. Poniard Pharmaceuticals, Inc. (NASDAQ...
-
J.P. Morgan Initiates Coverage on Metabolix at Neutral
Monday, December 12, 2011 - 9:38am | 68According to J.P. Morgan, Metabolix (NASDAQ: MBLX) coverage is initiated with a Neutral rating. J.P. Morgan said that it initiates coverage of Metabolix with a Neutral rating and a December 2012 price target of $5.00. “We expect Metabolix to reach positive EPS in 2016. Our Neutral rating in part...
-
JP Morgan Initiates Metabolix at Neutral, $5 PT
Monday, December 12, 2011 - 6:59am | 24JP Morgan has initiated coverage on Metabolix (NASDAQ: MBLX) with a Neutral rating and $5 price target.
-
Griffin Securities Initiates Ligand Pharma at Buy, $18 PT
Tuesday, November 22, 2011 - 11:31am | 25Griffin Securities has initiated coverage on Ligand Pharmaceuticals (NASDAQ: LGND) with a Buy rating and $18 price target.
-
A Peek Into The Market Before The Trading Starts
Tuesday, November 22, 2011 - 8:31am | 409Pre-open movers US stock futures are higher this morning, ahead of economic data and minutes from the recent meeting of the Federal Reserve's monetary-policy committee. Futures for the Dow Jones Industrial Average gained 40 points to 11,565.00 and S&P 500 index futures rose 6.60 points to 1,197...
-
Lexicon Announces Commencement of Rights Offering to Stockholders
Tuesday, November 22, 2011 - 7:55am | 196Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has commenced its previously announced rights offering pursuant to an effective registration statement and today began mailing a prospectus and other rights offering materials to its stockholders. In the rights offering,...
-
Edison Investment Research Expects Growth for Ligand Pharmaceuticals
Monday, November 14, 2011 - 9:31am | 142In a quickview note, Edison Investment Research expects Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to present growing revenues on broad pipeline opportunities. According to Edison, “End-September cash and equivalents was $13.6m; $15m+ is guided at end-FY11. FY11 guidance is for revenue of c $26m...
-
McNicoll, Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals
Friday, November 11, 2011 - 10:22am | 97A report from MLV & Co reiterates its Buy rating and $30 price target on Ligand Pharmaceuticals (NASDAQ: LGND). The report states, “During an AASLD Late-Breaker, Nazam Afdhal, M.D., presented the final results of the ENABLE 1 study and the preliminary results of the ENABLE 2 study. Our first-...
-
Maxygen Announces BARDA Decision Not To Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome
Wednesday, November 9, 2011 - 5:30pm | 108Maxygen, Inc. (Nasdaq: MAXY) today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome will not be...
-
Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting
Monday, November 7, 2011 - 10:02am | 189Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from preclinical studies on its Interleukin-1 Receptor Associated Kinase-4 (IRAK4) program was featured in an oral presentation today at the 2011 Annual Scientific Meeting of the American College of Rheumatology and the...
-
McNicoll Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals
Monday, November 7, 2011 - 9:06am | 91A report from MLV & Co reiterates its Buy rating and $30 price target on Ligand Pharmaceuticls (NASDAQ: LGND). The report states, “On Wednesday, November 2, Ligand announced that a Phase II trial of it's internal drug candidate, Captisol®-enabled, propylene glycol-free (PG-free) melphalan,...
-
Ligand Announces Successful Phase II Results for Captisol-Enabled Propylene Glycol-Free Melphalan
Wednesday, November 2, 2011 - 8:07am | 89Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced data from the Phase II study with its Captisol-enabled, propylene glycol-free melphalan. This Phase II study compared the safety, tolerability and pharmacokinetic profiles of a new PG-free melphalan intravenous formulation and the...
-
Jefferies Has Buy on Neurocrine Bio After Earnings
Tuesday, November 1, 2011 - 7:50am | 101Jefferies & Co. is out with a research report on Neurocrine Bio. (NASDAQ: NBIX) and it has a Buy rating and a $13 price target on shares. In a note to clients, Jefferies & Co. writes, "NBIX reported 3Q earnings, beating our estimates on earlier than anticipated recognition of milestones...
-
Ligand Enters into Platform Captisol License Agreement with SAGE Therapeutics
Wednesday, October 19, 2011 - 8:02am | 191Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into a Captisol license agreement with SAGE Therapeutics, Inc. for the development and commercialization of Captisol-enabled® therapeutics for a broad range of debilitating central nervous system conditions....